Extensive molecular profiling revealed that a number of components of the IGF signaling pathway, including insulin receptor substrate-2 (IRS2) and IGF-binding protein-5 (IGFBP5) among others, play key roles in determining the sensitivity of cancer cells to a humanized IGF1R antibody [26]. The gene discussed is IGF1; the disease is cancer.